Literature DB >> 35176549

A critical review of current technologies used to reduce ginkgotoxin, ginkgotoxin-5'-glucoside, ginkgolic acid, allergic glycoprotein, and cyanide in Ginkgo biloba L. seed.

Isaac Duah Boateng1.   

Abstract

The Ginkgo biloba has astonished scholars globally with enormous bioactives, with sales exceeding $10 billion since 2017. The Ginkgo biloba seed (GBS) is an essential part of culinary culture. Nevertheless, toxins in fresh Ginkgo biloba seed (GBS) have limited GBSs' daily consumption. Ginkgotoxin and ginkgotoxin-5-glucoside cause poisoning, tonic-clonic convulsions, and neurotoxic effects. Ginkgolic acid causes cytotoxicity and allergies. Allergic glycoprotein in GBS causes nausea, seizures, dyspnea, mydriasis, vomiting, and bellyache. The amygdalin-derived hydrocyanic acid cause dizziness, vomiting, cramping, and sleeping disorders. Food products are frequently exposed to various processing techniques to increase food safety and functionality. As a result, this review focused on the technologies that have been used to minimize toxins in GBS. In addition, a comparison of these techniques was made based on their benefits, drawbacks, feasibility, pharmacological activities, and future direction or opportunities to improve current ones were provided.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allergic glycoprotein; Cyanide; Ginkgo biloba L.; Ginkgo seed; Ginkgolic acid; Ginkgotoxin; Ginkgotoxin-5-glucoside; Pharmacological activities

Mesh:

Substances:

Year:  2022        PMID: 35176549     DOI: 10.1016/j.foodchem.2022.132408

Source DB:  PubMed          Journal:  Food Chem        ISSN: 0308-8146            Impact factor:   7.514


  2 in total

Review 1.  Biflavonoids: Important Contributions to the Health Benefits of Ginkgo (Ginkgo biloba L.).

Authors:  Dunja Šamec; Erna Karalija; Sabina Dahija; Sherif T S Hassan
Journal:  Plants (Basel)       Date:  2022-05-23

2.  Uncovering the pharmacology of Ginkgo biloba folium in the cell-type-specific targets of Parkinson's disease.

Authors:  Yu-Chen Yan; Zhi-Heng Xu; Jian Wang; Wen-Bo Yu
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.